Allarity Therapeutics, INC 10-Q quarterly reports

Allarity Therapeutics, Inc. filed its Q2 2026 10-Q, revealing continued net losses and a substantial accumulated deficit, while highlighting efforts to manage expenses and secure future funding.

Allarity Therapeutics reports Q1 2026 financial results, highlighting a $20 million capital raise and continued development of its stenoparib drug candidate.

Allarity Therapeutics reported a reduced net loss for the nine months ended September 30, 2025, while advancing its lead drug candidate stenoparib with FDA Fast Track designation and addressing internal control weaknesses.

Allarity Therapeutics reported a reduced net loss for the first half of 2025 and strategic advancements in its DRP platform, alongside a material weakness in internal controls and management changes.

Allarity Therapeutics announces its Q1 2025 financial results, highlighting a decrease in net loss compared to the previous year and providing updates on its clinical development programs and recent financial activities.

Allarity Therapeutics reported its third quarter 2024 results, including a significant impairment charge on intangible assets and ongoing efforts to secure additional funding.

Allarity Therapeutics reported its second quarter 2024 financial results, highlighting a reverse stock split, ongoing financial challenges, and an SEC investigation.

Allarity Therapeutics reported a net loss of $3.8 million for the first quarter of 2024, alongside ongoing efforts to secure additional funding.